Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Impact of Substitution Registry on the Receptor-Activation Profiles of Backbone-Modified Glucagon-like Peptide-1 Analogues.

Cary BP, Hager MV, Gellman SH.

Chembiochem. 2019 Jun 7. doi: 10.1002/cbic.201900300. [Epub ahead of print]

PMID:
31172641
2.

High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions.

Blaha DT, Anderson SD, Yoakum DM, Hager MV, Zha Y, Gajewski TF, Kranz DM.

Cancer Immunol Res. 2019 Jan;7(1):50-61. doi: 10.1158/2326-6066.CIR-18-0395. Epub 2018 Nov 13.

PMID:
30425106
3.

Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains.

Harris DT, Hager MV, Smith SN, Cai Q, Stone JD, Kruger P, Lever M, Dushek O, Schmitt TM, Greenberg PD, Kranz DM.

J Immunol. 2018 Feb 1;200(3):1088-1100. doi: 10.4049/jimmunol.1700236. Epub 2017 Dec 29.

4.

Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1.

Hager MV, Clydesdale L, Gellman SH, Sexton PM, Wootten D.

Biochem Pharmacol. 2017 Jul 15;136:99-108. doi: 10.1016/j.bcp.2017.03.018. Epub 2017 Mar 29.

5.

β-Arrestin-Biased Agonists of the GLP-1 Receptor from β-Amino Acid Residue Incorporation into GLP-1 Analogues.

Hager MV, Johnson LM, Wootten D, Sexton PM, Gellman SH.

J Am Chem Soc. 2016 Nov 16;138(45):14970-14979. Epub 2016 Nov 4.

6.

A potent α/β-peptide analogue of GLP-1 with prolonged action in vivo.

Johnson LM, Barrick S, Hager MV, McFedries A, Homan EA, Rabaglia ME, Keller MP, Attie AD, Saghatelian A, Bisello A, Gellman SH.

J Am Chem Soc. 2014 Sep 17;136(37):12848-51. doi: 10.1021/ja507168t. Epub 2014 Sep 5.

Supplemental Content

Loading ...
Support Center